Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neoplasms 3Venous Thrombosis 2Venous Thromboembolism 2Thrombosis 1Small Cell Lung Carcinoma 1Pulmonary Embolism 1Hemorrhage 1Carcinoma, Small Cell 1

Interventions

Dalteparin 10apixaban 9Tinzaparin 4Enoxaparin 4Heparin, Low-Molecular-Weight 3edoxaban 2abelacimab 2Rivaroxaban 2MAA868 2Dabigatran 2perflutren 1isoquercitrin 1enoxaparin sodium 1bemiparin 1Warfarin 1Sulfur Hexafluoride 1Rosuvastatin Calcium 1Hospitals 1Fondaparinux 1Fluorodeoxyglucose F18 1Educational Status 1Deoxyribonucleases 1Acetylcysteine 14-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pulmonary Embolism × bemiparin × Clear all
NCT00219973 2010-04-28

CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)

Rovi Pharmaceuticals Laboratories

Phase 3 Completed
526 enrolled
Classical hematology

Hemorrhage, Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡